Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 34,237,779 | $385,859,769 | -26% | 1.12% |
| 2. | QVT Financial Daniel Gold | 29,381,635 | $331,131,026 | -56% | 29.5% |
| 3. | Rubric Capital Management David Rosen | 20,370,336 | $229,573,687 | +15% | 3.47% |
| 4. | Two Seas Capital Sina Toussi | 10,598,040 | $119,439,911 | +5% | 2.01% |
| 5. | Anchorage Advisors Kevin Michael Ulrich And Anthony Davis | 4,832,642 | $54,463,875 | 21.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.07 | 3,315 | $49,957.05 | 17,287,081 | 2025-09-18 | Filing | |
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.06 | 118,418 | $2,020,211.08 | 1,504,959 | 2025-10-17 | Filing | |
| $17.05 | 318,282 | $5,426,708.10 | 1,504,959 | 2025-10-16 | Filing | |
| $16.93 | 414,683 | $7,020,583.19 | 1,504,959 | 2025-10-15 | Filing | |
| $16.25 | 20,727 | $336,813.75 | 1,504,959 | 2025-10-13 | Filing | |
| $16.30 | 104,940 | $1,710,522.00 | 1,504,959 | 2025-10-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 497,823 | $7,532,062 | 0.01% | |
| 2. | 198,500 | $3,003,305 | 1.01% | |
| 3. | 138,225 | $2,091,344 | 0.02% | |
| 4. | 90,228 | $1,365,150 | 0.24% | |
| 5. | 59,764 | $904,229 | 0% |
News See All
10 Best Stocks to Buy Under $20
On September 16, Ali Dibadj, Janus Henderson Investors CEO, joined 'Squawk Box' on CNBC to discuss the latest market trends and suggest that small and mid-cap stocks have enormous potential to deliver...
Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results
This followed positive results from the phase 3 clinical trial of drug candidate Brepocitinib for the treatment of dermatomyositis (DM), where it saw significant and constant developments in as early ...
Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat
Roivant Sciences Ltd.
7 Hot Healthcare Stocks to Buy Right Now
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Hedge Fund Resource Center Billionaire Hedge Funds
